Dr. Bearss is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1035 Lincolnton Rd
Salisbury, NC 28144Phone+1 704-637-1123Fax+1 704-637-1214
Education & Training
University of Texas Health Science Center at HoustonResidency, Internal Medicine/Pediatrics, 1992 - 1996- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1992 - 1995
The University of Toledo College of MedicineClass of 1992
Certifications & Licensure
NC State Medical License 1996 - 2025
MI State Medical License 1995 - 1997- American Board of Internal Medicine Internal Medicine
- American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2012-2015
- Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2012-2015
Publications & Presentations
PubMed
- 57 citationsDifferential Effects of p21WAF1/CIP1 Deficiency on MMTV-ras and MMTV-myc Mammary Tumor PropertiesDavid J. Bearss, Richard T. Lee, Dean A. Troyer, Richard G. Pestell, Jolene J. Windle
Cancer Research. 2002-04-01 - 1669 citationsDirect evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription.Adam Siddiqui-Jain, Cory L. Grand, David J. Bearss, Laurence H. Hurley
Proceedings of the National Academy of Sciences of the United States of America. 2002-09-03 - 748 citationsAn Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhi...Lauren Averett Byers, Lixia Diao, Jing Wang, Pierre Saintigny, Luc Girard
Clinical Cancer Research. 2013-01-01
Press Mentions
University of Utah to Speed Process of Bringing New Therapeutics to PatientsNovember 18th, 2020- Halia Therapeutics to Test HT-6184 in MDS Patients for First TimeDecember 12th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
